The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia

[1]  Xuening Wang,et al.  Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  S. Manenti,et al.  CHK1 as a therapeutic target to bypass chemoresistance in AML , 2016, Science Signaling.

[3]  S. Armstrong,et al.  Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML , 2016, Science Signaling.

[4]  J. Gribben,et al.  Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. , 2016, Cancer research.

[5]  G. Ossenkoppele,et al.  How I treat the older patient with acute myeloid leukemia. , 2015, Blood.

[6]  Łukasz Popiołek,et al.  Characteristics of hematopoietic stem cells of umbilical cord blood , 2014, Cytotechnology.

[7]  M. Cole,et al.  Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia , 2014, Leukemia.

[8]  J. Gribben,et al.  A Niche‐Like Culture System Allowing the Maintenance of Primary Human Acute Myeloid Leukemia‐Initiating Cells: A New Tool to Decipher Their Chemoresistance and Self‐Renewal Mechanisms , 2014, Stem cells translational medicine.

[9]  R. Rosenquist,et al.  Decreased survival in normal karyotype AML with single‐nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′‐nucleotidase , 2013, American journal of hematology.

[10]  Gary D Bader,et al.  Mir-126 Governs Human Leukemia Stem Cell Quiescence and Chemotherapy Resistance , 2013 .

[11]  Yun Dai,et al.  The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair , 2013, Molecular Cancer Therapeutics.

[12]  Atsushi Hirao,et al.  Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. , 2013, Cancer cell.

[13]  M. McDevitt,et al.  Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias , 2012, Clinical Cancer Research.

[14]  Erin L. Schenk,et al.  Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro , 2012, Clinical Cancer Research.

[15]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[16]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[17]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[18]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[19]  Francois Lassailly,et al.  "Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. , 2010, Blood.

[20]  Satoshi Tanaka,et al.  Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML , 2010, Nature Biotechnology.

[21]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[22]  J. Diffley,et al.  DNA replication as a target of the DNA damage checkpoint. , 2009, DNA repair.

[23]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[24]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[25]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[26]  M. Broggini,et al.  Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil , 2008, Clinical Cancer Research.

[27]  C. Cass,et al.  Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. , 2008, Cancer research.

[28]  K. Cimprich,et al.  The ATR pathway: fine-tuning the fork. , 2007, DNA repair.

[29]  Z. Estrov,et al.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. , 2006, Blood.

[30]  Junjie Chen,et al.  Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival , 2005, Molecular Pharmacology.

[31]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[32]  R. Mesa,et al.  Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. , 2005, Blood.

[33]  D. Parry,et al.  Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication Checkpoint , 2005, Cell cycle.

[34]  M. Broggini,et al.  Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53 , 2004, Cell cycle.

[35]  D. Loegering,et al.  Rad9 Protects Cells from Topoisomerase Poison-induced Cell Death* , 2004, Journal of Biological Chemistry.

[36]  Stephen J. Elledge,et al.  Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes , 2003, Science.

[37]  K. Kohn,et al.  UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. , 2002, Cancer research.

[38]  R. Willemze,et al.  Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia , 2002, European journal of haematology.

[39]  M. Heemskerk,et al.  Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. , 2002, Blood.

[40]  M. Berger,et al.  Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. , 2001, Cancer research.

[41]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[42]  W. Plunkett,et al.  S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. , 2001, Cancer research.

[43]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[44]  G. Crooks,et al.  A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. , 1995, Blood.

[45]  P. Thall,et al.  Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  W. Plunkett,et al.  Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. , 1988, Cancer research.

[47]  T. Robak,et al.  Current and emerging therapies for acute myeloid leukemia. , 2009, Clinical therapeutics.

[48]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[49]  R. Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[50]  L. Allen.  Stem cells. , 2003, The New England journal of medicine.

[51]  M. Konopleva,et al.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.

[52]  E. M. Smogorzewska,et al.  A Functional Comparison of CD 34 + CD 38-Cells in Cord Blood and Bone Marrow , 2022 .